2018年心脏病学领域：冠状动脉介入治疗 - Suppr

Suppr

超能文献

The year in cardiology 2018: coronary interventions.

作者信息

Dudek Dariusz, Dziewierz Artur, Stone Gregg, Wijns William

机构信息

Institute of Cardiology, Jagiellonian University Medical College, 17 Kopernika Street, Krakow, Poland.

2nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland.

出版信息

Eur Heart J. 2019 Jan 7;40(2):195-203. doi: 10.1093/eurheartj/ehy882.

DOI:10.1093/eurheartj/ehy882

PMID:30601991

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6321963/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d6d/6321963/b095f3ae6334/ehy882f5.jpg

相似文献

The year in cardiology 2018: coronary interventions.2018年心脏病学领域：冠状动脉介入治疗

Eur Heart J. 2019 Jan 7;40(2):195-203. doi: 10.1093/eurheartj/ehy882.

[Editorial: 2010 Guidelines on myocardial revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery].[社论：欧洲心脏病学会和欧洲心胸外科学会2010年心肌血运重建指南]

Turk Kardiyol Dern Ars. 2011 Jan;39(1):5-8.

Benefit of revascularization for stable ischaemic heart disease: the jury is still out.血运重建对稳定型缺血性心脏病的益处：尚无定论。

Eur Heart J. 2013 Jun;34(21):1534-8. doi: 10.1093/eurheartj/eht004. Epub 2013 Jan 29.

The role of percutaneous coronary intervention in managing patients with stable ischemic heart disease.经皮冠状动脉介入治疗在稳定型缺血性心脏病患者管理中的作用。

JAAPA. 2020 Jun;33(6):18-22. doi: 10.1097/01.JAA.0000662364.78880.57.

Overview: Japanese guidelines for myocardial revascularization to treat stable ischemic heart disease 2012.概述：《2012年日本治疗稳定型缺血性心脏病的心肌血运重建指南》

Gen Thorac Cardiovasc Surg. 2013 May;61(5):246-53. doi: 10.1007/s11748-012-0182-4. Epub 2012 Dec 12.

Joint ESC/EACTS guidelines on myocardial revascularization.欧洲心脏病学会（ESC）/欧洲心胸外科学会（EACTS）心肌血运重建指南

J Cardiovasc Med (Hagerstown). 2011 Apr;12(4):264-7. doi: 10.2459/JCM.0b013e328344e647.

Should ischemia be the main target in selecting a percutaneous coronary intervention strategy?在选择经皮冠状动脉介入治疗策略时，缺血应作为主要靶点吗？

Expert Rev Cardiovasc Ther. 2013 Aug;11(8):1051-9. doi: 10.1586/14779072.2013.814856.

Angiography-guided Multivessel Percutaneous Coronary Intervention Versus Ischemia-guided Percutaneous Coronary Intervention Versus Medical Therapy in the Management of Significant Disease in Non-Infarct-related Arteries in ST-Elevation Myocardial Infarction Patients With Multivessel Coronary Disease.在多支冠状动脉疾病的ST段抬高型心肌梗死患者中，非梗死相关动脉严重病变管理中血管造影引导下多支血管经皮冠状动脉介入治疗与缺血引导下经皮冠状动脉介入治疗及药物治疗的比较

Crit Pathw Cardiol. 2018 Jun;17(2):77-82. doi: 10.1097/HPC.0000000000000144.

Comparison of long-term clinical outcomes between revascularization versus medical treatment in patients with silent myocardial ischemia.比较无症状性心肌缺血患者血运重建与药物治疗的长期临床结局。

Int J Cardiol. 2019 Feb 15;277:47-53. doi: 10.1016/j.ijcard.2018.08.006. Epub 2018 Aug 3.

Systematic Evaluation of the Robustness of the Evidence Supporting Current Guidelines on Myocardial Revascularization Using the Fragility Index.使用脆弱性指数对支持当前心肌血运重建指南的证据稳健性进行系统评价。

Circ Cardiovasc Qual Outcomes. 2019 Dec;12(12):e006017. doi: 10.1161/CIRCOUTCOMES.119.006017. Epub 2019 Dec 11.

引用本文的文献

A novel glycyrrhizin acid-coated stent reduces neointimal formation in a rabbit iliac artery model.一种新型甘草次酸涂层支架可减少兔髂动脉模型中的内膜增生。

Front Pharmacol. 2023 May 17;14:1159779. doi: 10.3389/fphar.2023.1159779. eCollection 2023.

Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial.新一代生物可降解聚合物西罗莫司洗脱冠状动脉支架植入术后3个月与12个月双重抗血小板治疗的前瞻性多中心开放标签随机对照试验：TARGET DAPT试验方案

BMJ Open. 2019 Dec 17;9(12):e033774. doi: 10.1136/bmjopen-2019-033774.

本文引用的文献

2018 ESC/EACTS Guidelines on myocardial revascularization.2018年欧洲心脏病学会/欧洲心胸外科学会心肌血运重建指南。

EuroIntervention. 2019 Feb 20;14(14):1435-1534. doi: 10.4244/EIJY19M01_01.

Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.基于个体患者数据的荟萃分析：冠状动脉狭窄稳定患者采用血流储备分数指导的经皮冠状动脉介入治疗与药物治疗的比较。

Eur Heart J. 2019 Jan 7;40(2):180-186. doi: 10.1093/eurheartj/ehy812.

Accuracy of Fractional Flow Reserve Derived From Coronary Angiography.基于冠状动脉造影的血流储备分数的准确性。

Circulation. 2019 Jan 22;139(4):477-484. doi: 10.1161/CIRCULATIONAHA.118.037350.

Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease.冠状动脉计算机断层扫描血管造影在多支冠状动脉疾病中心脏团队决策中的应用。

Eur Heart J. 2018 Nov 1;39(41):3689-3698. doi: 10.1093/eurheartj/ehy581.

Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.冠状动脉生物可吸收支架的盲法结局和心绞痛评估：ABSORB IV 随机试验的 30 天和 1 年结果。

Lancet. 2018 Oct 27;392(10157):1530-1540. doi: 10.1016/S0140-6736(18)32283-9. Epub 2018 Sep 25.

Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial.血管内超声与血管造影指导药物洗脱支架置入术：ULTIMATE 试验。

J Am Coll Cardiol. 2018 Dec 18;72(24):3126-3137. doi: 10.1016/j.jacc.2018.09.013. Epub 2018 Sep 24.

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.超亲生物可吸收聚合物西罗莫司洗脱支架与薄型持久聚合物依维莫司洗脱支架比较。

J Am Coll Cardiol. 2018 Dec 25;72(25):3287-3297. doi: 10.1016/j.jacc.2018.09.019. Epub 2018 Sep 23.

Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.薄复合丝支架，耐用聚合物涂层（Resolute Onyx）与超薄钴铬支架，生物可吸收聚合物涂层（Orsiro）药物洗脱支架在所有伴有冠状动脉疾病的患者中的应用（BIONYX）：一项国际性、单盲、随机非劣效性试验。

Lancet. 2018 Oct 6;392(10154):1235-1245. doi: 10.1016/S0140-6736(18)32001-4. Epub 2018 Sep 22.

A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion: The REVASC Trial.一项评估慢性完全闭塞病变支架植入后左心室局部功能的随机临床试验：REVASC 试验。

JACC Cardiovasc Interv. 2018 Oct 8;11(19):1982-1991. doi: 10.1016/j.jcin.2018.05.041. Epub 2018 Sep 12.

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.经皮冠状动脉介入治疗后病变复杂性对围手术期不良事件的影响以及强效静脉内血小板腺苷二磷酸受体抑制剂的获益：来自 CHAMPION PHOENIX 试验的 10854 例患者的核心实验室分析。

Eur Heart J. 2018 Dec 7;39(46):4112-4121. doi: 10.1093/eurheartj/ehy562.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验